Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Adenoviridae Infections × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 262 Parkinson Disease 4, Autosomal Dominant Lewy Body 158 Melanoma 146 Neoplasms 115 Squamous Cell Carcinoma of Head and Neck 109 Colorectal Neoplasms 89 Neoplasm Metastasis 83 Carcinoma, Renal Cell 74 Triple Negative Breast Neoplasms 66 Head and Neck Neoplasms 64 Stomach Neoplasms 61 Lung Neoplasms 61 Breast Neoplasms 54 Ovarian Neoplasms 52 Carcinoma, Transitional Cell 43 Uterine Cervical Neoplasms 41 Pancreatic Neoplasms 37 Esophageal Neoplasms 37 Urinary Bladder Neoplasms 35 Endometrial Neoplasms 35 Carcinoma, Hepatocellular 34 Small Cell Lung Carcinoma 24 Carcinoma 21 Prostatic Neoplasms 20 Cholangiocarcinoma 20 Lymphoma 18 Carcinoma, Squamous Cell 18 Skin Neoplasms 14 Recurrence 14 Mesothelioma 14

Interventions

Gemcitabine 2 valrubicin 1 pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 fludarabine 1 atezolizumab 1 Tumor Necrosis Factor-alpha 1 Oncolytic Virotherapy 1 Mitomycin 1 Interferons 1 Interferon-beta 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05271318 2025-11-03

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡